GlassScriptPhysician profile
Jay Alton Bauerle
NPI 1265498604
$1,236.98
in general payments reported to CMS, 2019-2025
26 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $136 · 2021: $176 · 2022: $225 · 2023: $55.20 · 2024: $106 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $158.22 | 2021-2025 | Qulipta |
| Amgen INC. | $154.95 | 2019-2022 | |
| Sk Life Science, INC. | $99.22 | 2021-2025 | |
| Lundbeck LLC | $85.78 | 2019-2025 | Vyepti |
| Ucb, INC. | $78.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.98 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $62.31 | 2019-2023 | Austedo |
| Genzyme Corporation | $53.97 | 2019-2020 | |
| Kyowa Kirin, INC. | $51.04 | 2019-2022 | |
| Emd Serono, INC. | $43.33 | 2020-2024 | |
| Avanir Pharmaceuticals, INC. | $40.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.84 | 2020 | |
| Amneal Pharmaceuticals LLC | $38.44 | 2020-2022 | |
| Biogen, INC. | $35.16 | 2019-2022 | |
| Lilly USA, LLC | $34.41 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.31 | 2019 | |
| Tanabe Pharma America, INC. | $21.68 | 2020 | |
| Pfizer INC. | $21.55 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Acadia Pharmaceuticals INC | $17.45 | 2024 | Nuplazid |
| Abbott Laboratories | $15.37 | 2022 | |
| Cycle Pharmaceuticals INC | $14.77 | 2024 | Tascenso Odt |
| Celgene Corporation | $13.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.24 | 2021 | |
| Mdd US Operations, LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Bauerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.